New injection could transform life for bleeding disorder patients
NCT ID NCT07115004
Summary
This study is testing whether a new injection called VGA039 can safely prevent bleeding episodes in people with von Willebrand disease, a genetic bleeding disorder. The trial will follow 60 patients aged 12-75 who experience frequent bleeding episodes. Participants will first be observed for 24 weeks without treatment, then receive weekly VGA039 injections for 49 weeks to see if they experience fewer bleeds.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASE (VWD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arkansas Children's Hospital
RECRUITINGLittle Rock, Arkansas, 72202, United States
-
Hemophilia Center of Western PA
RECRUITINGPittsburgh, Pennsylvania, 15213, United States
-
Science 37, Inc. (Virtual Clinical MetaSite)
RECRUITINGMorrisville, North Carolina, 27560, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Washington Center for Bleeding Disorders
RECRUITINGSeattle, Washington, 98101, United States
Conditions
Explore the condition pages connected to this study.